Identification of the Novel Synthetic Opioid N ‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Blake Curtis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory, Australia. Hauptthemen laut MEDLINE: Analgesics, Opioid, Illicit Drugs, Pyrrolidines, Substance Abuse Detection. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ACT Health.
Abstract (Originalsprache)
2‐Benzylbenzimidazole opioids and related derivatives, also known as ‘nitazenes’, present a growing threat to public health. Emerging in Europe in 2019, the nitazene group of drugs is a recent addition to the novel synthetic opioid class and has been associated internationally with adverse effects in drug users, overdose clusters and significant mortality. The high potency of many nitazene derivatives, which can in many cases exceed that of fentanyl, poses a significant challenge to the public health and early warning systems used to detect and respond to the emergence of new high‐risk substances. This report describes close collaboration between an Australian drug checking service and a nearby university laboratory to identify and characterise the novel synthetic opioid N ‐pyrrolidino isotonitazene in an expected oxycodone sample presented by a member of the public. Though no prior publications are available describing the presence of this nitazene in the drug market, previously reported in vitro evaluation of this compound reveals it to be among the most potent nitazene opioid agonists known. The study highlights the rapid response possible though engaging drug users with drug checking services as a market monitor and early warning system to alert health services and the broader community to the presence of unexpected, high‐risk substances. Integration of well‐resourced and supported drug checking services provides a powerful approach to tackle the public health threats associated with novel synthetic opioids and other drugs of concern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory, Australia.
- CanTEST Health and Drug Checking Service, Canberra, Australian Capital Territory, Australia.
- Emergency Department, North Canberra Hospital, Canberra, Australian Capital Territory, Australia.
- School of Medicine and Psychology, Australian National University, Canberra, Australian Capital Territory, Australia.
- The Australian Drug Observatory, Australian National University, Canberra, Australian Capital Territory, Australia.
ORCID-Profile: Malcolm D McLeod
Förderung
- ACT Health
Zitieren
APA
Curtis, B., Lawes, D. J., Caldicott, D., & McLeod, M. D. (2025). Identification of the Novel Synthetic Opioid N ‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service. Drug Testing and Analysis. https://doi.org/10.1002/dta.3910
Vancouver
Curtis B, Lawes DJ, Caldicott D, McLeod MD. Identification of the Novel Synthetic Opioid N ‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service. Drug Testing and Analysis. 2025. doi:10.1002/dta.3910
BibTeX
@article{Curtis2025,
author = {Curtis, Blake and Lawes, Douglas J and Caldicott, David and McLeod, Malcolm D},
title = {Identification of the Novel Synthetic Opioid N ‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3910}
}
EUVIMED